Navigation Links
Ardea Biosciences Announces Upcoming Corporate Meetings
Date:5/14/2008

very and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment of HIV in a human micro-dose pharmacokinetic study and have selected it as a development candidate. We are also investigating RDEA806 for the treatment of gout. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers for the treatment of inflammatory diseases. We have evaluated our second generation MEK inhibitor, RDEA436, for the treatment of cancer and inflammatory diseases in a human micro-dose pharmacokinetic study, and have selected it as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinica
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
2. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
3. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
4. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
5. Numira Biosciences Names New Board Member
6. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
7. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
8. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
9. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
10. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... California (PRWEB) July 14, 2014 ... to reach USD 4,285.1 million by 2020 growing ... new study by Grand View Research, Inc. Steady ... biology for bioinformatics R&D programs designed for sequencing ... number of clinical studies in pharmacogenomics and pharmacokinetics ...
(Date:7/14/2014)... Austin, TX (PRWEB) July 14, 2014 Kenn ... practices recently. The video is meant to describe the business ... real estate broker and national speaker – Kenn Renner – ... of branding, marketing, and goal setting techniques. , Investing in ... extra money. Some people do it as their career, while ...
(Date:7/14/2014)... NATURALLY, DANNY SEO, a new magazine ... with a Fall issue that hits newsstands nationwide on ... the healthy, natural and good for you life with ... beauty, travel, home, and entertaining all through Danny’s unique ... “Instead of gimmicky weight loss tips and fluffy celebrity ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 According to the ... is a helpful guide that features a series of new ... in its review that this book can help readers understand ... of high blood pressure, and effective methods to control ... are reviewed now by Vkool, was penned by Ken Burge, ...
(Date:7/14/2014)... July 14, 2014 Vaginal Mesh ... against seven different pelvic mesh manufacturers in the U.S. ... & Schulte LLC. The federal complaints are pending against ... 2327), American Medical Systems (MDL No. 2325), and C.R. ... there are 58,262 Vaginal Mesh lawsuit claims pending, according ...
Breaking Medicine News(10 mins):Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5
... linked to hypertension years later, study finds , MONDAY, ... and Afghanistan who go into combat are more likely ... than those who serve in supporting roles, a new ... appeared to be a unique risk factor for newly ...
... Surging obesity rates have reversed gains, study finds , MONDAY, ... heart disease may be on the wane, experts say, with ... are now in the clear when it comes to heart ... bear much of the blame for the downturn, the researchers ...
... Analysis notes tamoxifen, raloxifene can up chances of other ... Medications given to women at high risk for developing ... drugs carry other health risks, a new analysis suggests. ... at numerous published studies, including randomized clinical trials and ...
... Global meeting ... ... Scientists and Technologists, , ,WHAT: 21st International Radon Symposium , , ,WHEN: September 20-23, ... Station, , ,WHY: Radon remains a serious, global health threat and remains the ...
... 14 Misonix, Inc. (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... who wishes to remain anonymous, donated the majority of the ... NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement ...
... , LOS ALTOS, Calif., Sept. 14 ... Higgins, PhD has been named Chief Operating ... as InteKrin,s Chief Scientific Officer after joining the Company earlier ... has had increasingly broad operational and strategic responsibility in key ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3Health News:InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer 2
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative forty-five percent ... of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative ...
... Florida and Scripps Research in La ... ... and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. ... Scripps Research,Institute, a non-profit biomedical research organization, today announced,that an agreement ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: